Ten Diabetes Warning Letters in One Day: The Sweep

who received letters in the september 7 2021 sweep?

Ten dietary-supplement sellers got an FDA warning letter on the same day for diabetes claims.

We counted ten letters in FDA's filtered export for September 7, 2021, and checked each recipient name against the agency's public warning-letter index before listing it here. All ten carry the identical subject line, Unapproved New Drugs/Misbranded, issued by the Center for Food Safety and Applied Nutrition — the food and supplement arm of FDA, not its prescription-drug reviewers.

No single company on the list dominates the diabetes-supplement category, and the range runs from recognizable retail brands to single-product storefronts most readers have never heard of.

what charge did fda bring in every one of the ten?

Every one of the ten letters charges the same two-part violation: the product is an unapproved new drug, and its labeling is misbranded.

FDA's theory in this niche starts with how the agency defines disease in the first place. Under 21 CFR 101.93(g)(1), FDA calls a disease 'damage to an organ, part, structure, or system of the body such that it does not function properly' — and type 2 diabetes plainly fits that description. A diabetes claim makes the product a drug under FD&C Act section 201(g)(1)(B), and because none of the ten had drug approval, each became a 'new drug' under section 201(p), sold in violation of sections 301(d) and 505(a).

Diabetes needs a licensed practitioner's supervision, and FDA treats that alone as impossible to fix with better instructions.

That last point is the misbranding half of the charge: under section 502(f)(1), a product aimed at a condition that isn't "amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner" can't carry adequate directions for lay use, full stop. Rewriting the dosage panel doesn't cure it — removing the diabetes claim does.

how does a same-day sweep get assembled in the first place?

A same-day sweep starts with a keyword pull, not a tip about one brand. FDA's food-safety reviewers run full-text searches — "diabetes," "A1c," "blood sugar," "insulin" — across supplement websites, marketplace listings and social accounts, then route whatever surfaces to a small team that drafts a batch of letters on the same claim theory. The Lysulin letter shows how far that net reaches: FDA quoted an Instagram post carrying the hashtags "#type2diabetic #diabetescare" and "#insulindependent #diabetes #insulinresistance" as evidence of intended use, alongside a customer testimonial reporting an HbA1c drop from 10.5% to 9.5%, and noted separately that "the Federal Trade Commission reviewed your websites in August 2021" — the same month, the same properties.

We checked FTC's case index for a matching companion action tied to this specific sweep and found none; the Commission's diabetes enforcement runs through separate matters like Nobetes, not a coordinated one-day filing alongside FDA. We could not confirm how many of the other nine recipients drew that same FTC review — only the Lysulin letter states it in writing, and confirming the rest would mean pulling each company's FTC correspondence file directly, which isn't published alongside FDA's letters.

Organic posts count as much as paid ads once the agency treats a domain, a blog and a Facebook page as one file.

That keyword-first mechanic is a large part of why warning-letter counts are a bad risk ranking by niche — the number reflects what got searched that quarter, not what's actually circulating in the market.

what claim language appears to have triggered inclusion?

FDA quoted Lysulin's own copy — 'The combination and high level of these active ingredients have been shown to help maintain healthy A1c blood sugar levels in diabetics and prediabetics' — as the central evidence in the letter, and the reason is precise: strip the six words "in diabetics and prediabetics" and the rest reads close to language FDA itself has already blessed.

FDA drew that exact boundary in its own 2000 rulemaking. It permits 'use as part of your diet to help maintain a healthy blood sugar level' as lawful phrasing, and it separately forbids the same idea once it's aimed at a person taking insulin — the final rule explains that referring to a drug used for a disease implies the supplement treats that disease too.

The word that fails a blood-sugar claim is never "lowers" or "reduces" — it's the audience you name.

The same audience-naming problem shows up one layer deeper, in the mechanism story built around the disease rather than the outcome claim — a pattern examined in why only one nutra niche blames a living organism, where a "root cause" reframe tries to license a treatment claim while carefully avoiding the word treat.

why does this make keyword-level copy risk higher than brand-level risk?

Copy risk in this niche tracks the words on the page, not the size of the company behind it. FDA's search tooling doesn't distinguish a seven-figure brand from a single-SKU storefront — both surface on the same "diabetes" or "A1c" query, and both get the same letter template once they do.

That split also matters because the two federal agencies audit different things: FDA rules the label, FTC rules your ad, and a phrase that clears FDA's structure/function test can still fail FTC's substantiation bar the moment it runs as paid media.

You might assume a competitor's clean warning-letter history proves the copy is safe. It doesn't — the absence of a letter usually means the keyword hasn't been searched yet, not that the claim already passed review.

how does the november 2022 cholesterol sweep compare?

The November 2022 cholesterol sweep ran the same mechanic at roughly half the size — five letters instead of ten, issued the same way by the same food-safety office on a single day.

what should a buyer running a glucose offer do the week a sweep lands?

Audit your own copy against the population-reference pattern before checking anyone else's, since that's the one thread FDA has already proven it searches for.

The pill isn't the only exposure here. FTC's parallel action against a publisher, not a supplement seller, shows the same theory reaching an information-product funnel: the Commission said the operation 'tricks seniors into buying books, newsletters, and other publications that falsely promise a cure for type 2 diabetes,' and the defendants paid more than $2 million in refunds. A diabetes-reversal advertorial or VSL funnel carries the same exposure as the capsule it's selling.

• Search your own site, blog and every linked social account for "diabetic," "A1c," "insulin" and "prediabetes" — FDA reads them as one file, not separate surfaces.
• Check testimonials and reposted UGC for lab-value claims, an A1c number or a dosage reduction, the way FDA quoted a customer's own HbA1c drop in the Lysulin letter.
• Confirm your ad copy doesn't position the product as a substitute for, or booster of, insulin or metformin — the two moves 21 CFR 101.93(g)(2)(vi)-(vii) name directly.
• If you're buying media on a competitor's formula, check its FDA letter history first; a warning letter is a standing disqualifier under Google's unapproved-substances policy, not something that expires.
• For the exact sentence FDA has already cleared, start from [the one blood sugar sentence FDA wrote out for you](/niches/the-one-blood-sugar-sentence-fda-wrote-out-for-you) instead of reverse-engineering your own from a warning letter.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Testosterone Booster Offers: Scaling Ads & Angles 2026, CBD Affiliate Offers: Ads That Run Despite the Bans, Mushroom Supplement Offers: Lion's Mane Ads Scaling, Semaglutide Affiliate Offers: CPA Payouts Compared, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.